<DOC>
	<DOCNO>NCT02550860</DOCNO>
	<brief_summary>The epidermal barrier efficacy determine physicochemical property epidermal lipid matrix , among ω-6 essential fatty acid ( EFAs ) play key role . Inversely , ω-3 EFAs find epidermis . For patient receive lipid-containing parenteral nutrition ( LCPN ) , improvement epidermal barrier infusion appropriate intravenous fat emulsion ( IVFE ) could many application clinical nutrition , mainly limit water loss patient receive long-term LCPN help electrolyte water balance . The objective interventional clinical trial evaluate epidermal barrier function patient receive long-term LCPN compare two composition IVFE : ( ) soybean oil ( SO ) -based IVFE ( Medialipide ) ( ii ) fish oil ( FO ) -containing IVFE ( Lipidem ) . Epidermal barrier function assess transepidermal water loss ( TEWL ) measurement skin surface , validate marker epidermal barrier efficacy . The two IVFE ( SO-based FO-containing ) compare use randomize double blind crossover design , use patient control . Each IVFE allocate 3-month period , allow sufficient timeframe epidermal complete renewal . Patient 's epidermal red blood cell EFA profile determinate order facilitate result interpretation .</brief_summary>
	<brief_title>Influence Fish Oil Based Intravenous Fat Emulsions Epidermal Barrier Function</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>Patient sever chronic intestinal disease require long term parenteral nutrition Receiving home lipid contain parenteral nutrition ( LCPN ) , regardless currently infuse intravenous fat emulsion With stable dose LCPN least 1 month recruitment time Administered least 4 day week central venous access , least 150 mL lipid per parenteral nutrition bag lipid . Age &gt; 18 Being available 2 medical consultation 6 month period Who give write informed consent participate study without legal protection Social security coverage Lesser expect parenteral nutrition length duration entire trial Dermatological criterion : History skin disease ( atopic dermatitis , psoriasis ) evolve skin disease , break inflamed skin TEWL measurement site , Use topical cream TEWL measurement site , Skin systemic allergy ( asthma ) Contraindication one select intravenous fat emulsion : Severe dyslipidemia ; Uncontrolled diabetes ; Sepsis ; Severe hepatic impairment ; Major blood clot disorder ; Egg protein , soybean , peanut fish hyper sensibility ; Serum creatinine clearance &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>intravenous fat emulsion</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>skin barrier function</keyword>
	<keyword>essential fatty acid</keyword>
	<keyword>transepidermal water loss</keyword>
</DOC>